Kaleido Biosciences

63 articles with Kaleido Biosciences

• Kaleido Biosciences to Participate in the JMP Securities Life Sciences Conference

  6/10/2021

  Kaleido Biosciences, Inc. today announced that CEO Dan Menichella will deliver a corporate presentation at the JMP Securities Life Sciences Conference at 4PM ET on Thursday, June 17.

• Kaleido Biosciences Reports First Quarter 2021 Financial Results

  5/4/2021

  --Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109’s potential to reduce healthcare utilization and recovery time; initiating IND application to support further development-- --Topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis on track for mid-2021--

• Kaleido Biosciences Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic Therapies (MMT™) in Preventing Febrile Neutropenia

  4/20/2021

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to treat disease and improve human health, today announced a research collaboration with researcher Robert Jenq, M.D. Professor of Genomic Medicine, at The University of Texas MD Anderson Cancer Center

• Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit

  4/15/2021

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that CEO Dan Menichella will participate in an analyst-led fireside chat on Thursday, April 22 at the Jefferies Microbiome-Based Therapeutics Summit.

• 

  Clinical Catch-Up: March 22-26

  3/29/2021

  There was a fair amount of clinical trial news last week. Here’s a look.
• 

  With Variants on the Rise, Researchers Sharpen New Weapons Against COVID-19

  3/24/2021

  With the rise of mutant strains of SARS-CoV-2 and the unlikelihood of 100% compliance in getting vaccines out, investigators are focusing on developing even better vaccines and new drugs that might be able to knock back the disease. Here’s a look.

• Kaleido Biosciences Reports Positive Results from Non-IND Study Demonstrating a Reduction in COVID-19 Related Healthcare Utilization and Recovery Time in Patients with Mild-to-Moderate COVID-19 and One or More Comorbidity

  3/24/2021

  KB109 demonstrated favorable safety and tolerability profile Kaleido intends to file an Investigational New Drug (IND) application, with the goal of advancing KB109 directly into a pivotal registration program Company to host conference call today at 8:30am ET

• Kaleido Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results

  3/3/2021

  Topline data from two ongoing COVID-19 studies with KB109 expected in Q1 2021 KB295 study in patients with ulcerative colitis remains on track with topline data anticipated mid-year 2021

• Kaleido Biosciences to Present at Chardan’s 3rd Annual Microbiome Medicines Summit

  3/1/2021

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that Dan Menichella, President and Chief Executive Officer of Kaleido will present a corporate overview and host 1x1 meetings with investors during Chardan’s 3rd Annual Microbiome Medicines Summit.

• Kaleido Biosciences Announces the Exercise of the Underwriters’ Option to Purchase Additional Shares of Common Stock

  2/11/2021

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that, in connection with its previously announced underwritten public offering of common stock, the underwriters have fully exercised their option to purchase an additional 787,500 shares of common stock from the Company.

• Kaleido Biosciences Announces Pricing of Public Offering of Common Stock - Feb 04, 2021

  2/4/2021

  Kaleido Biosciences, Inc., a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $11.50 per share.

• Kaleido Biosciences Announces Proposed Public Offering of Common Stock

  2/3/2021

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that it intends to sell, subject to market and other conditions, $50 million of shares of its common stock in an underwritten public offering.

• Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” Conference

  1/20/2021

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” conference this afternoon at 12:15 p.m. MST. The presentation will provide an update on progress with the Kaleido MMTTM platform,

• Kaleido Biosciences Announces Positive Interim Results of Controlled Study of KB109 in Patients with Mild-to-Moderate COVID-19

  1/14/2021

  Preliminary analysis (n=176) demonstrates favorable safety and tolerability; data provide a strong signal of clinical benefit for subjects reporting one or more comorbidities Topline data from full study population of 350 patients and results of second study of KB109 are expected in the first quarter of 2021

• Kaleido Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/5/2021

  Kaleido Biosciences, Inc., announced that Dan Menichella, Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. EST on Thursday, Jan. 14, 2021.

• Kaleido Biosciences Announces Completion of Enrollment of 350 Subjects in Controlled Study of KB109 in the Treatment of Mild-to-Moderate COVID-19Topline data for two studies of KB109 are expected in the first quarter of 2021

  1/4/2021

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that completion of enrollment of 350 subjects in the controlled clinical study K031 evaluating Microbiome Metabolic Therapy (MMT™) candidate KB109 in the treatment of mild-to-moderate COVID-19.

• Kaleido Biosciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

  11/24/2020

  Kaleido Biosciences, Inc., announced that Dan Menichella, Chief Executive Officer, will participate in a fireside chat at the virtual Piper Sandler 32nd Annual Healthcare Conference taking place November 30-December 3, 2020.

• Kaleido Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  11/2/2020

  Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced financial results for the third quarter 2020 and provided a corporate update. “Kaleido continues to build momentum with the development of interventions based on our Microbiome Metabolic Therapy, or MMT™, platform and evaluate the highly diverse applications of

• Kaleido Biosciences Announces Data from MMT Programs Accepted for Presentation at Upcoming Scientific Conferences

  10/7/2020

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that data from its Microbiome Metabolic Therapy (MMT™) programs for hepatic encephalopathy, cardiovascular and liver disease, and COVID-19 disease have been accepted for poster presentations at upcoming scientific conferences.

• Kaleido Biosciences Provides Update on KB109 Clinical Data Timeline

  10/6/2020

  Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced an update to its ongoing COVID-19 clinical development program evaluating KB109 when added to supportive self-care (SSC) in outpatients with mild-to-moderate COVID-19 disease. Updated projections for enrollment of the multi-center K031 clinical study of approximately 350 patients indicated that top-line data will be available in the first quarter of 2021. Previous projections had indic